Tags

Type your tag names separated by a space and hit enter

Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial.
Gynecol Endocrinol. 2017 Nov; 33(11):872-876.GE

Abstract

To compare the therapeutic efficacy of clomiphene citrate (CC) and letrozole (LE) on ovulation, pregnancy, and live birth in women with polycystic ovary syndrome (PCOS); and to ensure if LE can replace CC as the first-line therapy for ovulation induction in these women. This is a prospectively, randomized, controlled trial in the tertiary hospital. Two-hundred and sixty-eight anovulatory PCOS patients were treated by CC or CC plus metformin and LE or LE plus metformin for three continuous cycles or conception; their ovulation rates, pregnancy rates, and live birth rates were calculated and compared. No significant difference was noted among the four groups regarding to the baseline data of clinical manifestations, serum sex hormone levels, and serum insulin levels. A total of 240 patients completed the therapies. The ovulation rate was significantly higher in the group LE than the group CC; however, no significant difference was noted between the groups LE and CC, CC, and CC + MET, or LE and LE + MET in the pregnancy rate, abortion rate, and live birth rate. No birth defect was found in the total of 63 newborns. CC regimen was still recommended to be the first-line therapy of ovulation induction for PCOS.

Authors+Show Affiliations

a Department of Obstetrics and Gynecology , West China Second University Hospital of Sichuan University , Sichuan Sheng , PR China.a Department of Obstetrics and Gynecology , West China Second University Hospital of Sichuan University , Sichuan Sheng , PR China. b Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital , PR China.a Department of Obstetrics and Gynecology , West China Second University Hospital of Sichuan University , Sichuan Sheng , PR China.a Department of Obstetrics and Gynecology , West China Second University Hospital of Sichuan University , Sichuan Sheng , PR China.a Department of Obstetrics and Gynecology , West China Second University Hospital of Sichuan University , Sichuan Sheng , PR China.a Department of Obstetrics and Gynecology , West China Second University Hospital of Sichuan University , Sichuan Sheng , PR China.a Department of Obstetrics and Gynecology , West China Second University Hospital of Sichuan University , Sichuan Sheng , PR China.a Department of Obstetrics and Gynecology , West China Second University Hospital of Sichuan University , Sichuan Sheng , PR China.

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

28557652

Citation

Liu, Chang, et al. "Comparison of Clomiphene Citrate and Letrozole for Ovulation Induction in Women With Polycystic Ovary Syndrome: a Prospective Randomized Trial." Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology, vol. 33, no. 11, 2017, pp. 872-876.
Liu C, Feng G, Huang W, et al. Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. Gynecol Endocrinol. 2017;33(11):872-876.
Liu, C., Feng, G., Huang, W., Wang, Q., Yang, S., Tan, J., Fu, J., & Liu, D. (2017). Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology, 33(11), 872-876. https://doi.org/10.1080/09513590.2017.1332174
Liu C, et al. Comparison of Clomiphene Citrate and Letrozole for Ovulation Induction in Women With Polycystic Ovary Syndrome: a Prospective Randomized Trial. Gynecol Endocrinol. 2017;33(11):872-876. PubMed PMID: 28557652.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. AU - Liu,Chang, AU - Feng,Guimei, AU - Huang,Wei, AU - Wang,Qiuyi, AU - Yang,Shiyuan, AU - Tan,Jing, AU - Fu,Jing, AU - Liu,Dong, Y1 - 2017/05/30/ PY - 2017/5/31/pubmed PY - 2018/7/10/medline PY - 2017/5/31/entrez KW - Polycystic ovary syndrome KW - clomiphene citrate KW - induced ovulation KW - letrozole KW - metformin SP - 872 EP - 876 JF - Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology JO - Gynecol Endocrinol VL - 33 IS - 11 N2 - To compare the therapeutic efficacy of clomiphene citrate (CC) and letrozole (LE) on ovulation, pregnancy, and live birth in women with polycystic ovary syndrome (PCOS); and to ensure if LE can replace CC as the first-line therapy for ovulation induction in these women. This is a prospectively, randomized, controlled trial in the tertiary hospital. Two-hundred and sixty-eight anovulatory PCOS patients were treated by CC or CC plus metformin and LE or LE plus metformin for three continuous cycles or conception; their ovulation rates, pregnancy rates, and live birth rates were calculated and compared. No significant difference was noted among the four groups regarding to the baseline data of clinical manifestations, serum sex hormone levels, and serum insulin levels. A total of 240 patients completed the therapies. The ovulation rate was significantly higher in the group LE than the group CC; however, no significant difference was noted between the groups LE and CC, CC, and CC + MET, or LE and LE + MET in the pregnancy rate, abortion rate, and live birth rate. No birth defect was found in the total of 63 newborns. CC regimen was still recommended to be the first-line therapy of ovulation induction for PCOS. SN - 1473-0766 UR - https://www.unboundmedicine.com/medline/citation/28557652/Comparison_of_clomiphene_citrate_and_letrozole_for_ovulation_induction_in_women_with_polycystic_ovary_syndrome:_a_prospective_randomized_trial_ L2 - https://www.tandfonline.com/doi/full/10.1080/09513590.2017.1332174 DB - PRIME DP - Unbound Medicine ER -